2-Tert-butylazepane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环庚烷
• 英文名称: 2-Tert-butylazepane
• 化学式: C₁₀H₂₁N
• mdl: MFCD02663705
• 分子量: 155.28
• InChiKey: VGMDCKSILGQMBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• BENZTHIAZOLE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE
  申请人：Przytulinska Magdalena K.

  公开号：US20100183743A1

  公开（公告）日：2010-07-22

  Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed.

  本发明公开了一种具有公式（I）结构的聚（ADP-核糖）聚合酶抑制剂，制备它们的方法以及使用它们治疗患者的方法。
• BENZOXAZOLE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE
  申请人：Przytulinska Magdalena K.

  公开号：US20110293744A1

  公开（公告）日：2011-12-01

  Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed.

  本发明公开了一种具有式（I）结构的聚（ADP-核糖）聚合酶抑制剂，其制备方法以及使用它们治疗患者的方法。
• PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS
  申请人：Quattropani Anna

  公开号：US20120071460A1

  公开（公告）日：2012-03-22

  The present invention relates to pyrazole oxadiazoles derivatives of Formula (I), and their use for treating multiple sclerosis and other diseases, wherein R 1 , R 2 and R 3 are as defined in the description.

  本发明涉及式（I）的吡唑噁二唑衍生物，以及它们用于治疗多发性硬化症和其他疾病的用途，其中R1、R2和R3如描述中所定义。
• Compounds useful for treating neurodegenerative disorders
  申请人：Bronk Brian Scott

  公开号：US20130060020A1

  公开（公告）日：2013-03-07

  The present invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein R x is as defined and described herein, compositions thereof, and methods of using the same.

  本发明提供了公式I的化合物：或其药学上可接受的盐，其中Rxis的定义和描述如本文所述，以及其组合物和使用方法。
• SUBSTITUTED 2-(CHROMAN-6-YLOXYL)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：SANOFI

  公开号：US20180148440A1

  公开（公告）日：2018-05-31

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.